Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy

Jessica R. McCann[1], Chengxin Yang[2], Nathan Bihlmeyer[3], Runshi Tang[11], Tracy Truong[2], Jie An[3], Jayanth Jawahar[1], Olga Ilkayeva[3, 10], Michael Muehlbauer[3], Zheng Zheng Hu[1,7], Holly Dressman[1,7], Lisa Poppe[3], Joshua Granek[2,7], Lawrence A. David[1,7], Pixu Shi[2,7], Pinar Gumus Balikcioglu[4], Svati Shah[3], Sarah C. Armstrong[5,6], Christopher B. Newgard[3], Patrick C. Seed[8,9*], and John F. Rawls[1,7*]

[1] Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA

[2] Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA

[3] Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA

[4] Division of Pediatric Endocrinology and Diabetes, Duke University Medical Center, Durham, NC, USA

[5] Division of General Pediatrics, Duke University Medical Center, Durham, NC, USA

[6] Duke Clinical Research Institute, Duke University, Durham, NC, USA

[7] Duke Microbiome Center, Duke University School of Medicine, Durham, NC, USA

[8] Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

[9] Stanley Manne Children's Research Institute, Ann and Robert H. Lurie Children's Hospital, Chicago, IL, USA

[10] Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC, USA

[11]Department of Statistics, University of Wisconsin-Madison, Madison, WI

*****Corresponding Authors

ABSTRACT

BACKGROUND: Towards improving outcomes for adolescents with obesity, we aimed to define metabolic and microbiome phenotypes at baseline and post-weight loss intervention.

METHODS: The Pediatric Obesity Microbiome and Metabolism Study enrolled 220 adolescents aged 10-18 with severe obesity (OB) and 67 healthy weight controls (HWC). Blood, stool, and clinical measures were collected at baseline and after a 6-month intervention for the OB group. Serum metabolomic and fecal microbiome data were analyzed for associations with BMI, insulin resistance, and inflammation. Fecal microbiome transplants were performed on germ-free mice using samples from both groups to assess weight gain and metabolomic changes.

RESULTS: Adolescents with OB exhibited elevated serum branched-chain amino acids (BCAA) but reduced ketoacid metabolites (BCKA) compared to HWC. This pattern was sex- and age-dependent, unlike adults with OB, who showed elevated levels of both. The fecal microbiomes of adolescents with OB and HWC had similar diversity but differed in membership and functional potential. FMT from OB and HWC donors had similar effects on mouse body weight, with specific taxa linked to weight gain in FMT recipients. Longitudinal analysis identified metabolic and microbial features correlated with changes in health measures during the intervention.

CONCLUSION: Adolescents with OB have unique metabolomic adaptations and microbiome signatures compared to their HWC counterparts and adults with OB.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT03139877 (Observational Study) and NCT02959034 (Repository)

FUNDING SOURCES:

American Heart Association Grants: 17SFRN33670990, 20PRE35180195

National Institute of Diabetes and Digestive and Kidney Diseases Grant: R24-DK110492

INTRODUCTION

Current knowledge about the physiology of obesity and treatment response is dominated by studies conducted in adults. Since the 1960s, studies have established that elevation of circulating branched-chain amino acids (BCAA: valine, leucine, and isoleucine) and various products of their catabolism are associated with adult obesity, metabolic syndrome, and future development of T2D (1-3). The ketoacid metabolites of BCAA (BCKA) have been measured in fewer studies but are also reported to be elevated in adults with obesity (4, 5). Adults who lose weight via dietary and exercise interventions with or without bariatric surgery experience a reduction in BCAA and BCKA levels (6-8). BCAA-deficient diets in rodents confirm a causal relationship between obesity and T2D (9, 10). Circulating glutamate, a product of BCAA metabolism, is also associated with both insulin resistance and obesity in adults (11). Finally, some short and medium chain acylcarnitines, such as the C3 and C5 species generated from BCAA metabolism, are consistently found in a metabolite principal component associated with adult T2D and insulin resistance (3, 12). Together, these results establish that adults with obesity have a metabolic profile consisting of elevated BCAA, BCKA, and associated acylcarnitines and amino acids.

Adolescence is a critical window during which time successful treatment of obesity dramatically reduces the risk for adult obesity, T2D, and cardiovascular mortality, and significant reduction of childhood obesity by late adolescence reduces risk to levels similar to children who never experienced obesity (13, 14). A similar magnitude of weight loss in adults with obesity does not lead to the same degree of risk reduction, suggesting that obesity in earlier life may be driven by physiological mechanisms that are still reversible before adulthood. Yet, little is known about how the metabolic pathways of obesity differ between adolescence and adulthood.

Limited prior work has indicated that obesity in youth aged 4-19 years is characterized by increased BCAA and acylcarnitine catabolism and changes in nucleotides, lysolipids, and inflammatory markers also seen in adults with obesity, as well as reduced fatty acid catabolism that may be unique to obesity in children (15). Recent work comparing male and female adolescents with obesity in the age range of 12-18 years who underwent a 6-month lifestyle intervention program suggests a sex difference in the baseline level of circulating BCKA, with males having higher levels than females despite similar BMI profiles (16). In addition, a recent

study showed an elevation in urinary BCAA and BCKA levels in female adolescent subjects with type 2 diabetes compared to obese, non-diabetic, or lean controls, accompanied by diversion of tryptophan metabolism from the serotonin to the kynurenine pathway (17). These metabolic indices may be related to the higher risk of T2D in obese adolescent females than in adolescent males or relatively higher rates of anabolic metabolism in males. However, the similarities and differences in obesity physiology between adolescents and adults remain unclear, especially with respect to sex and age.

Several studies in adults have reported gut microbiome alterations associated with obesity and related diseases (reviewed in (18)). Fecal microbiome transplant (FMT) from adult humans with and without obesity to germ-free (GF) mouse recipients has indicated that the microbiome can causally contribute to obesity and associated metabolic disease. GF mice receiving FMT from adult donors with obesity gain more weight, gain more fat mass, and have distinct microbiota-linked changes to serum metabolite profiles than those receiving FMT from a healthy weight adult donor (19-22). However, it remains unknown if the microbiome causally contributes to obesity physiology during earlier adolescent stages. Based on the lack of gut microbial diversity differences we saw in our preliminary cohort analysis (23) we hypothesized that adolescent obesity would not be directly correlated with gut dysbiosis to the same extent as observed in adults.

We established the Pediatric Obesity Microbiome and Metabolism Study (POMMS) to test the hypothesis that adolescents with obesity have metabolic and microbiome characteristics at baseline and following weight loss intervention that distinguish them from adults with obesity (23). Our study cohort was drawn from the Duke Children's Healthy Lifestyles program, which offers multi-component behavioral, pharmacotherapeutic, and surgical treatment options as per the current American Academy of Pediatrics guidelines for youth aged 23 and younger with obesity (24). By studying the microbiome and metabolome in this diverse population, we sought to identify new prognostic and therapeutic targets for greater obesity-associated disease risk reduction and reversibility in the most affected populations. Further, adolescents tend to be treatment naïve. Thus, their clinical and metabolic measures are less complicated by drug effects. The study

design, data collection, and demographics of the POMMS cohort were previously described (23). Here, we report our findings from the complete metabolome and microbiome datasets at baseline and after intervention.

RESULTS

Clinical lab measure differences between control and treatment groups at baseline. The POMMS clinical cohort was recruited upon referral to the Duke Healthy Lifestyles Clinic in Durham, North Carolina, USA. Details concerning recruitment, treatment plans, and demographics of our study cohort have been previously reported (23) and are summarized in Figure 1A and Supplemental Table 1. Participants with obesity (OB, n= 220) and healthy weight controls (HWC, n= 67) were well-matched according to race and ethnicity. However, the OB group was significantly more female-identifying and younger than the HWC group (Table S1). CRP, HbA1c, ALT, LDL, triglyceride, insulin, systolic, and diastolic blood pressures were elevated in the OB group compared to the HWC group after covariates adjustment (Table 1). HDL was significantly reduced in the OB group. The triglyceride/HDL ratio is another metric of metabolic health, and high levels are associated with a higher risk of insulin resistance in children and adults (25-27). We found this ratio to be higher at baseline in adolescents with OB. We also found fasting glycerol levels were significantly higher in the OB cohort in a targeted lab analysis (Supplemental Table S1.1), suggesting higher levels of lipolysis in adolescents with OB (28). However, these two groups had no significant difference in the fasting glucose level. These results suggest that even though several metrics associated with OB in adults were significantly higher in the OB cohort when compared to HWC, high BMI alone is not enough to significantly confer the dysregulated fasting glucose commonly observed in adults with obesity (29).

Serum metabolites reveal distinct adolescent sex- and age-dependent associations with BMI, insulin resistance, and inflammation. In an adjusted analysis of serum metabolites in OB and HWC adolescents at baseline, elevations in BCAA valine (Val), the amino acids tyrosine (Tyr), glutamine/glutamate (Glx), and phenylalanine (Phe), and C3 (propionyl, a bioproduct of BCAA catabolism) and C8:1 acylcarnitines were all significantly and positively associated with higher %95th BMI. In contrast, higher serum levels of the amino acids glycine (Gly), serine (Ser), histidine (His), methionine (Met), and several even chain acylcarnitines were

significantly associated with lower %95th BMI (Fig 1C). The ketoacids of BCAAs leucine (KIC) and isoleucine (KMV) were also significantly associated with lower %95th BMI. This is in notable contrast to adults in which these ketoacids are typically positively associated with obesity and T2D (4, 7). Several of the metabolites associated with %95th BMI at baseline were also associated with HOMA-IR at baseline, including those correlated with lower levels (Gly, Ser, and acylcarnitines C20 and C6-DC/C8-OH) and higher levels (Val, Tyr, Phe, Glx, C3) of HOMA-IR (Fig 1D). Elevated HOMA-IR was also significantly associated with the levels of leucine/isoleucine (Leu/Ile) and proline (Pro), but not with the BCKA. In adults, elevated BMI and HOMA-IR have similarly been associated with elevated BCAA, Phe, Tyr, and C3 acylcarnitine (3-5). However, adult BMI and HOMA-IR are also associated with high levels of BCKA as noted above, but we did not see this in our adolescent cohort. These data suggest that adolescents with OB have metabolic features similar to adults with obesity including elevated BCAA and associated metabolites, but also display adaptations that differ from adults including reduced BCKA in association with high BMI.

HbA1c is a predictive measure for IR in adults, but its use as a measure of metabolic health during adolescence can sometimes be difficult to interpret, as high levels can occur in adolescents with a normal weight and fasting glucose profiles, especially among Black youth (30). Only the amino acids Leu/Ile, Phe, and Tyr were significantly associated with a higher HbA1c ratio (Fig 1C), but the acylcarnitines C3-C5, and BCKA KIV were negatively (but not significantly) associated with higher HbA1c, again suggesting metabolites associated with IR and OB in adults are not significantly associated with key clinical measures of metabolic syndrome in our adolescent cohort.

CRP, a clinical marker of general inflammation, significantly correlated with fewer metabolites either positively (Val, Phe, Asx) or negatively (acylcarnitine C20, His, Gly, and alanine Ala) at baseline (Fig 1E). Some of these significant CRP-metabolite associations were similar in directionality to those with %95th BMI or HOMA-IR (Val, Phe, His, Gly, C20), whereas others were unique to CRP (Asx) or exhibited reversed directionality compared to HOMA-IR (Ala). Whereas only a subset of acylcarnitine species measured here were significantly associated with these three clinical measures, we observed that most acylcarnitines were generally

positively correlated with CRP but negatively correlated with HOMA-IR and %95th BMI. Therefore, the general association trend between most serum acylcarnitines and CRP is inverse to that of %95th BMI, HbA1c, and HOMA-IR.

BCAA metabolism in adolescent obesity is sex and age dependent.

Prior work (16) suggests that there is an interaction between obesity status, sex and age that influences BCAA and their related metabolites. To further assess these metabolic signatures in our adolescent cohort, we tested whether interaction between case-control status and age would affect metabolite levels. We found initially that these variables were driven by levels in HWC males (Fig 2, Table S2). We also found that serum levels of the BCAA, along with several other amino acids and acylcarnitines involved in BCAA metabolism (Fig 2A), were significantly varied by case-control status and age. Males generally had higher levels of most affected amino acids and their metabolites. When we analyzed raw data and adjusted only for multiple comparisons, males with HWC status had significantly higher levels of Leu/Ile, Glx, and the BCAA metabolite C3 than OB males, as well as the ketoacids of Leu and Ile (KIC and KMV, respectively) (Fig 2B-J). Following adjustment for age and race, several of these relationships remained significant, including higher levels of Leu/Ile, C8:1-OH/C6:1DC, C18, C20-OH/C18-DC, Met, His, Om, and Cit in HWC males compared to males with OB (Table S2.1). Because adults with OB tend to have higher levels of BCKA compared to HWC (4-8), we tested if the opposite trends in the adolescent data were still seen in older adolescents by assessing metabolites affected by the interaction of obesity, sex, age, and Tanner (pubertal) stage (31). We found that the amino acids Leu/Ile, His, Orn, Val, Met, Cit, and Phe, and the acylcarnitines C18, C20-OH/C18-DC, C16, C18:1, and C8:1-OH/C6:1DC were significantly affected by the overall interaction between HWC v OB status and sex (Fig 3A, Table S2). Second stage testing further delineated the role of status and sex for each indicated metabolite (Table S2.1). Based on the interaction of Tanner stage and HWC v OB status, KMV, the ketoacid of Ile, was significantly affected in participants within Tanner stages 4 and 5, suggesting that older teens had a greater affected difference in serum levels of this ketoacid (Fig 3B, Table S3). To test whether BCKA are

associated with sex and obesity at younger ages, we analyzed metabolite data from the Hearts and Parks (HP) Study (32), which included children starting at age 5, as well as several individuals that were cross-recruited into the POMMS observational trial. Serum metabolomic samples from HP were randomized among and analyzed with the POMMS cohort samples to reduce drift from batch effects. When we analyzed data from children aged 5-9 years, we found that the ketoacid KMV was no longer affected by age in the younger children. Still, the BCAA acylcarnitine metabolite C3 was affected by sex in the older age group (Fig 3C). These results indicate that obesity-associated differences in BCAA and related metabolite levels are sex-dependent and emerge later in adolescence.

Microbiome alpha and beta diversity were similar between OB and HWC adolescents, but taxa and microbial features were distinct between cohorts. We analyzed 16S rRNA gene amplicon sequence data from 786 fecal samples covering 50 HWC participants at baseline, all 5 timepoints from 57 participants with OB that contributed fecal samples at 0, 1.5, 3, 4.5 and 6 months of the POMMS study, and at least 0 and 6 month timepoints from 140 participants in the OB cohort. As in the interim analysis (23), we observed no significant differences in either alpha or beta diversity based on HWC v OB status at baseline, sex, or age at entry (Fig S1A and data not shown). When we tested whether specific bacterial lineages might be associated with %95th BMI at baseline, we found that adolescents with a higher BMI had significantly higher relative abundances of several family-level taxa, while the HWC cohort had significantly higher abundance in members of the Lachnospiraceae and Bacteroiodaceae (Fig S1B).

To gain further insight into these microbial communities, shotgun DNA sequencing data were obtained for 396 participant-derived fecal samples, including quality controls for sequencing fidelity and sampling replication. High quality sequences were obtained for 140 OB at baseline and 6 months, and 50 HWC participants at the baseline time point. Consistent with the 16S rRNA data, alpha and beta diversity did not significantly differ between the OB and HWC cohorts (Fig S2), and profiles of the most abundant family- and species-level taxa were generally similar between the two cohorts (Fig S3). Further analysis determined, however, that participants from the OB cohort had a significantly higher Firmicutes to Bacteroidetes ratio than HWC (P=

0.001). ALDEx2 (33), ANCOM-BC (34), and corncob (35) analyses were employed to identify differential taxa between the two groups at baseline. The methods detected an increased relative abundance of genera *Ligilactobacillus* and reduced *Alistipes* among the OB participants. Of the *Ligilactobacillus*, the species *L. ruminis* was most prevalent (>90% of samples), and of *Alistipes*, the species *A. finegoldii* was found in most samples (>90%). Notably, *Ligilactobacillus* and *Alistipes* abundance remained positively and negatively correlated, respectively, with %95th BMI (Fig 4A).

To reduce data dimensionality, taxa and functional capacity of the gut microbiomes were clustered, and the resulting factors were associated with clinical scores at baseline (Fig 4C, Fig S4, and Tables S4.1-4.3). Though microbial species diversity was similar between the two cohorts at baseline (Fig S2), there were two taxonomic clusters significantly associated with either %95th BMI or CRP as continuous variables (Fig 4C, with factors defined in Tables S4.1-S4.4). Further clustering of serum metabolomics, KEGG orthology functions, and taxa were associated with clinical variables and we found several clusters of co-varying taxa, genes, phages, and serum metabolites indicating that there is cross talk between metabolomic status and the microbiome (Fig S4, with weights and factors defined in “Supplemental Tables – Factor Weights”). Using a random forests machine learning model, we generated a model that predicts OB v HWC status, which was significantly enriched for pathways involved in microbial amino acid synthesis, two-component signaling, lipopolysaccharide biosynthesis, and bacterial cell membrane components. Notably, several genes required for microbial synthesis of BCAA and tryptophan were independently identified as significant contributors to this model (Fig S5B and Table S4.5), mirroring prior research that associated gut microbial BCAA synthesis genes with T2D in adults (36). No factors were significantly associated with HOMA-IR score at baseline (data not shown).

Donor-status independent metabolites and microbes were associated with weight gain and percent adipose in FMT recipient mice. FMT experiments previously demonstrated that microbial content can confer phenotypic and metabolomic traits of the donor, at least temporarily, to germ-free mouse (20-22) and human (37) recipients. However, all prior studies that examined the role of the microbiota in obesity used fecal samples

from adult donors. We hypothesized that adolescent microbiota, influenced by host growth and development, are optimized for peak energy harvest regardless of OB and HWC status, and that weight gain may not differ between mice receiving FMT from HWC or OB donors. To test this, we chose FMT samples of male and female donor adolescents from the HWC group, with %95th BMI that ranged from the 20th to the 80th percentile, and from the OB group (see Table S5 for FMT donor demographics). Male C57Bl/6 mice aged 5-7 weeks were weighed, gavaged with 150-200 ul of donor slurry (Fig 5A), housed under gnotobiotic conditions and fed a sterilized standard chow diet ad libitum, and then euthanized at 2 weeks post gavage. We weighed the ex-germ-free mice every 3-4 days post gavage (Fig 5B). While there was a non-significant trend towards more weight gained (Fig 5D) and heavier epididymal fat pads (Fig 5E) in mice that received donor slurry from adolescents with OB, we did not see significant changes in weight gain or fat pad mass associated with donor OB vs HWC status or with sex or race of donor (data not shown). The strongest predictor of weight gain across all recipient mice was the starting weight of the recipient (R^2=0.72, p<0.0001). Comparing metabolite profiles across all recipient mice, levels of serum amino acids Gly, Tyr, Asx, and Arg, as well as acylcarnitines C16:1, C10:3, C8:1C4-DC/Ci4-DC were negatively associated with more weight gained (Fig.5C).

We were intrigued to see that microbiome samples from some individual adolescent donors were able to confer greater weight gain over others, raising the possibility that some transplanted microbes might be associated with weight gain. Indeed, we did detect a microbial signature associated with weight gained, percent adipose (Table 2), and serum metabolite features. Fecal microbial alpha diversity was significantly higher in mice receiving donor microbiomes from HWC donors than OB donor recipients (Fig S6C). We found Bray-Curtis dissimilarity to be significantly associated with percent weight gain and donor weight group (p-values <0.01) but not adipose percent change (p-value >0.1). We also saw significant engraftment of *Akkermansia*, *Ruminoccocus*, and *Bacteroides* in fecal samples 2 weeks post gavage when compared to the composition of the donor sample, and a relative decrease in members of the *Blautia* genus throughout engraftment (Fig S6B). Only two taxa were significantly negatively associated with weight gain across all recipient mice – ASV 153 *Barnesiella* sp. (log 2 fold change -0.80, padj. 5.2^{-13}) and ASV 21 *Collinsinella aerofaciens* (log 2 fold change -0.19, padj 0.02). We also found several microbes significantly associated with clusters of co-varying

metabolites (Fig S6C and Table S5.2). Many of these microbes are significantly associated with metabolite cluster 1, made up of mostly even medium- to long-chain acylcarnitines. Cluster 2 was defined by the BCAA valine, BCKA KIC, KIV, and KMV, along with BCAA metabolite 3-HIB (38). This metabolite cluster was both positively and negatively associated with several *Blautia* and *Bacteroides* ASVs (Fig 4H).

Serum levels of aromatic and branched chain amino acids increase with increased BMI and IR, over the 6 month observational study period, while levels of even chain acylcarnitines increase when BMI and IR scores go down. One goal of this project was to determine whether metabolic shifts co-occur with improvements in health metrics during weight loss intervention. We first examined whether a change in metabolites correlated with a positive or negative change in BMI, HOMA-IR, or CRP. We found that, in general, aromatic and branched chain amino acids increased with higher BMI, higher HOMA-IR, and higher HbA1c over the 6 months observational study period, while several even chain acylcarnitines and glycine increased with clinical improvements (decreases) in BMI and HOMA-IR. While the majority of participants either maintained or reduced their %95th BMI score, HOMA-IR increased for most participants over the observation period (Fig 6A-B and Fig S8), which is a common phenomenon during adolescence (39-41). We also noted that several acylcarnitine metabolites positively associated with increased CRP, while acylcarnitines tended to shift in the opposite direction in correlation with decreases in BMI or HOMA-IR (Fig 6DF).

Microbiome taxa and pathways at baseline predict change in health measures over the observational period, while distinct sets of taxa and features are associated with change in CRP.

We analyzed the metagenomic data to determine if there were any microbial taxa or pathways at baseline that were significantly associated with change in BMI, HOMA-IR, CRP, or HbA1c, all significant indicators of metabolic health in adolescents (42). While there were no significant associations with change in HOMA-IR, we found that several microbes at baseline were predictive of either increases or decreases in the BMI, HbA1C, or CRP levels, with some taxa shared between changes in 2 measures (Fig 7B). For example, *Bacteroides thetaiotaomicron*, *finegoldii*, and *uniformis* as well as *Parabacteroides distasonis* and *merdae* were all associated with change in CRP and %95th BMI, but often in opposite directions. In addition, *Anaerostipes*

hadrus, *Blautia producta*, and *Escherichia* virus Lambda_4A7 were all commonly associated with a change in HbA1c (Fig S7C) and CRP (Figure S7D). Notably, several taxa were associated with changes in CRP but not with other clinical metrics, suggesting that the subset of microbes that potentially predict changes in this inflammatory marker are separate from those associated with BMI or other metabolic health indicators.

DISCUSSION

Based on studies of adult obesity indicating that the microbiome plays a strong role in driving obesity-associated phenotypes, similar microbiome and metabolic coupling has been presumed in adolescent obesity. We studied a cohort of adolescents with and without obesity to compare their metabolic and microbiome states with the hypothesis that the obesity-associated adolescent metabolome and microbiome differ from that reported in adults with obesity. We further postulated that the adolescent metabolic rearrangement associated with obesity would not be associated with gut dysbiosis to the same extent as observed in adults, suggesting a decoupling of metabolic shaping in adolescent obesity and the gut microbiome.

BCAA and BCKA may have an anticorrelated signature in obesity that is unique to adolescents. In our study of adolescents with obesity, we found that serum levels of the BCAA and their direct metabolites, the BCKA, significantly differed between the OB and HWC cohorts, but the BCKA skewed higher among the healthy weight group. At the same time, BCAA were higher among the teens with obesity. Circulating levels of BCAA have been associated with obesity, IR, and T2D in adults since the late 1960s (1, 3). At baseline, BCAA and aromatic amino levels are prognostic for the development of type 2 diabetes in adults in long-term studies (2, 43), and this same metabolite cluster also predicts improvements in HOMA-IR in response to weight loss (44). While circulating amino acids are often measured in metabolite studies of adults, it is less common that those data sets also include BCKA. When measured, BCKA levels tend to mirror BCAA levels in adults with obesity, with both being higher than in healthy-weight controls (7) and both dropping significantly after effective treatments for obesity and T2D such as an exercise-based intervention (6) or bariatric surgery (45, 46). This may be related to obesity-driven changes in expression and activity of the kinase (branched-chain ketoacid dehydrogenase kinase, BCKDK) and phosphatase (protein phosphatase Mg2+/Mn2+ dependent 1 kinase, PPM1K) enzymes that control phosphorylation state and activity of branched-chain ketoacid dehydrogenase

(BCKDH), the rate-limiting enzyme of BCAA catabolism (47, 48). Similarly, studies in adult rodent models, including *ob*/*ob* mice and Zucker-obese rats, show combined elevations of BCAA and BCKA in the obese state (7, 48). Our finding of anticorrelated BCAA and BCKA levels in adolescents with obesity indicates a metabolic phenotype during these critical early stages that is distinct from that found in obese adults. In agreement with our results, a recent study in adolescents suggested that high BCAA and low Gly should be included as part of a metabolic signature that could predict β-cell failure (49).

We found that the intersection of sex and obesity status plays a significant role in BCAA and BCKA levels. Our data suggest that these effects do not emerge until puberty onset, as we found that there were few sex-based differences in BCAA-BCKA metabolites in kids aged 6-9 years from the AHA Hearts and Parks Study (32). Emerging experimental data suggest that there is sexual dimorphism in circulating levels of BCAA and their metabolism. Kobayashi and colleagues demonstrated that female sex hormones affected the diurnal regulation of the enzyme complex responsible for BCAA metabolism in rat liver, whereas gonadectomy of adult male rats did not affect circadian BCAA metabolism (8). Human data examining the serum metabolomic differences of 1756 adult participants (903 females and 853 males) from the population-based Cooperative Health Research in the Region of Augsburg Germany (KORA) F4 study suggested that BCAA metabolites were significantly higher in males and were significantly associated with male sex when taken as a group (5, 50). In another study, exercising men had higher rates of leucine oxidation than women (51). Focusing on children and teens, Newbern and colleagues (52) published that in a cohort of 82 teens with obesity, BCAA levels and byproducts of BCAA catabolism are higher in teen boys with obesity than in girls of comparable BMI. A subsequent study by the same group found that plasma levels of KMV, the ketoacid of isoleucine, went down in males but not in females when measured at the 6-month follow-up visit (16). The mechanisms underlying these emerging sex—and age-associated differences in BCAA metabolism remain unknown, but they could represent useful diagnostic and prognostic markers of obesity-associated pathologic progression.

We also found that the majority of the POMMS OB cohort had an increase in HOMA-IR score over the observational period (Fig 6 and Fig S8). A reduction in insulin sensitivity during puberty is an established

phenomenon that reaches a nadir at Tanner stage 3 (39-41). Thus, the increase in HOMA-IR (decline in sensitivity) over the observational period is not necessarily associated with metabolic disease in our cohort.

Reduced serum glycine is a common signature of obesity in adolescents and adults. We also found that serum glycine levels were significantly reduced in adolescents with obesity when compared to the HWC group. This observation has been documented in adult obesity (53-55), and glycine levels increase after weight loss and improvement with insulin sensitivity (6, 45, 46, 56, 57). A recent study showed that elevations of BCAA in obesity activate glycine consumption to replenish pyruvate needed for the alanine transaminase reaction and nitrogen unloading in skeletal muscle (58) (Fig 2A). Treatment with a specific BCAT inhibitor that interferes with BCAA transamination increases muscle and plasma glycine levels in Zucker fatty rats (10). Our data suggest that the reciprocal relationship between BCAA catabolism and glycine levels exists in adolescents despite their divergent BCKA signatures.

Acylcarnitine data from adult humans suggests that serum or plasma elevation of C3-C5 species, which are derived from the metabolism of BCAA and other amino acids (59), are often found in principal component metabolite clusters along with the BCAA and aromatic amino acids that is associated with obesity, insulin resistance, and T2D (3, 44, 60). Low-grade chronic inflammation is a hallmark of T2D (61, 62) and obesity (63), and CRP levels drop with weight loss (64, 65). We identified an acylcarnitine signature associated with CRP levels at baseline (Fig 1) and with change in CRP during intervention (Fig 6) that was distinct from the acylcarnitine species associated with both baseline and during-study changes in BMI and HOMA-IR. Fewer data sets incorporate metabolites when comparing HWC and OB in children and adolescents. One of the most comprehensive reports describes a cohort of 803 Hispanic children in the Viva la Familia study, ranging in age from 4-19y and split between HWC and OB at a single timepoint (15). They examined 304 named serum metabolites and found that their OB subjects had increased BCAA and acylcarnitine metabolites and increased inflammation markers. They suggest that unlike adults with obesity, their pediatric cohort had reduced fatty acid catabolism. The Viva la Familia study did not include BCKA measurements, nor did it include longitudinal

sampling or interventions. The data sets reported here therefore provide new insights into the relationships between BCAA, BCKA, and acylcarnitine species in the context of pediatric obesity and intervention outcomes.

Functional microbiome signatures are associated with obesity and metabolic signatures. Fecal microbiome transplants from adult lean donors and donors with obesity into germ-free mice demonstrate that the microbiome can contribute to weight gain and adiposity and affects the serum metabolomic profiles of the recipients (20, 22, 66). While we did not see significant differences in alpha and beta diversity between our adolescent case and control groups, the functional suite of genes represented in the microbiome associated with obesity in adolescence may still play a role in the serum availability of some obesity-related metabolic biomarkers. We found significant associations between BMI status and microbial genetic ability to synthesize several amino acids, including the BCAA and tryptophan (Supplemental Fig 5B). Research in pigs suggests that approximately 30% of dietary glycine is consumed by the small intestinal microbiota (67, 68), while other work in both conventionally-raised and germ-free mice and rats suggests that the gut microbiome contributes on the order of grams per day of essential amino acids to the nutritional pool (66).

In the future, longitudinal experiments that examine both amino acids and lipid metabolite levels at time points from a young age through adulthood using a diet-induced obesity pre-clinical model could help clarify the role of age and sex in BCAA and acylcarnitine metabolism. Such studies could help define a transition from high BCAA - low BCKA in youth to high BCAA - high BCKA in adult obesity. Such experiments could also incorporate microbiome analysis over time to determine if the gut microbial ecology changes across life stages and whether these changes are associated with metabolic shifts.

Metabolites and microbiome associations in children and adolescents – microbiome across HWC and OB teens is less differential than in adult cohorts. Our results provide important insights into the composition and function of the gut microbiome of pediatric obesity. Previous studies suggest that the gut microbiome undergoes changes between adolescence and adulthood in healthy individuals (69). Adults with obesity and healthy weight display substantial differences in gut microbiome diversity and composition (22, 70, 71), and those differences are distinct from adolescents with obesity or healthy weight (72). Our comparisons of adolescents with obesity and healthy weight detected no differences in diversity and limited differences in

composition and functional potential. Previous studies examining the role of the microbiome in the development of obesity in germ-free animal models demonstrated that the microbiome from adult donors with OB contributes to more weight gain, higher adiposity, and higher circulating BCAA compared to a microbiome transplant from a lean adult donor (19, 22). We found that while there were individual adolescents whose microbiome sample could confer greater weight gain over others, there was no specific association between weight gain and donor BMI in our studies here. Together, these results raise the possibility that the gut microbiomes harbored by adolescents with obesity do not yet have sufficient compositional or functional changes to causally affect host metabolism, whereas microbiome changes and causal consequences increase progressively as individuals with obesity progress into adulthood. In the future, it will be important to determine if the ability of the gut microbiome to contribute to obesity phenotypes is due to microbiome functional differences (72) or differences in host growth and physiology during that critical stage. The resulting information could inform efforts to target the microbiome in treatment of obesity.

Recently, several medications were FDA-approved for the treatment of obesity in adolescents aged 12 and older. While these agents are remarkably effective in reducing body mass index (BMI), questions remain about the necessary duration of treatment. Some studies have suggested that a normalization of BMI prior to adulthood, in effect, “resets” the metabolic pathways and may offer hope for these teens to avoid the need for lifelong medication. In the future, it will be interesting to determine how these newly approved medications affect the distinct metabolic and microbial phenotypes described here.

In conclusion, we found that adolescents with OB have unique metabolomic adaptations when compared to their HWC counterparts and adults with OB. We also found that while both OB and HWC teens had similar measures of gut microbiome diversity, there were distinct microbial taxa and functional differences that defined OB v HWC status. We also found that the suite of metabolites and gut microbial taxa associated with inflammatory status as measured by CRP level had little overlap with those associated with insulin resistance scores and BMI. Longitudinal analysis revealed metabolic and microbial features that correlate with or predict changes in health measures over the observational period. Data derived from this cohort will help to develop an

improved understanding of the physiological pathways of adolescent obesity and may provide insights that will inform future clinical decision-making.

METHODS

Sex as a biological variable. Both male and female participants were included in this study. All relevant data was adjusted for sex, age, and race.

Serum metabolomics: All serum metabolomics assays were performed at the Duke Molecular Physiology Institute. Serum samples were randomized and analyzed for the conventional metabolites nonesterified fatty acids (NEFA), glucose, insulin, glycerol, blood urea nitrogen (BUN), 3-hydroxy butyrate, total ketones, triglycerides, and uric acid. The samples were run in seven daily batches of approximately 76 sera per batch. Samples were run on a Beckman autoanalyzer from individual tubes, with pooled serum controls inserted at the beginning, middle, and end of the sequence. Reagents for measuring for total ketones, beta-hydroxybutyrate (3-HB), and nonesterified fatty acids (NEFA) were from Fujifilm (Osaka, Japan). Samples were additionally assayed for insulin using kits from Meso Scale Discovery (Rockville, MD). All samples were refrozen afterwards for later insulin immunoassays on 96-well plates. Corresponding to each batch of metabolites were two insulin plates (e.g. 1-2 for Batch 1, 3-4 for 2, and so on) on which the 76 samples were assayed, 38 per plate. Controls were run twice on each insulin plate, placed at the beginning and end. Insulin was measured by immunoassay using reagents and electrochemiluminescent imager from Meso Scale Discovery (Rockville, MD). Glucose was measured on a Beckman DxC 600 clinical analyzer (Brea, CA). HOMA-IR was calculated as (fasting insulin in units/liter x fasting glucose in mg/deciliter)/405 (73).

Serum samples were analyzed for amino acids and acylcarnitines in a targeted assay using labeled standards as described (23). Branched-chain keto acids were analyzed by LC-MS/MS as described (10). Briefly, 20 µl of plasma containing isotopically labeled internal standards KIC-d3, KIV-5C13 (Cambridge Isotope Laboratories), and KMV-d8 (Toronto Research Chemicals) was precipitated with 150 µl of 3M PCA. 200 µl of 25 M *o*-phenylenediamine (OPD) in 3M HCl was added to the supernatants, and the samples were incubated at

80°C for 20 minutes. Keto acids were extracted with ethyl acetate as previously described (74). The extracts were dried under nitrogen, reconstituted in 200 mM ammonium acetate, and analyzed on a Waters Xevo TQ-S triple quadrupole mass spectrometer coupled to a Waters Acquity UPLC system. The analytical column (Waters Acquity UPLC BEH C18 Column, 1.7 µm, 2.1 × 50 mm) was used at 30°C. 10 µl of the sample was injected onto the column and eluted at a flow rate of 0.4 ml/min. The gradient consisted of 45% eluent A (5 mM ammonium acetate in water) and 55% eluent B (methanol) for 2 min., followed by a linear gradient to 95% B from 2 to 2.5 min., held at 95% B for 0.7 min., returned to 45% A, and then the column was re-equilibrated at initial conditions for 1 minute. The total run time was 4.7 min. Mass transitions of *m/z* 203 → 161 (KIC), 206 → 161 (KIC-d3), 189 → 174 (KIV), 194 → 178 (KIV-5C13), 203 → 174 (KMV), and 211 → 177 (KMV-d8) were monitored in a positive ion electrospray ionization mode.

Fecal DNA preparation and sequencing: Fecal DNA was collected and aliquoted as described (23). DNA was recovered from approximately 200mg of fecal material using the DNeasy Power Soil Pro kit (Qiagen). Bacterial community composition in isolated DNA samples was characterized by amplification of the V4 variable region of the 16S rRNA gene by polymerase chain reaction using the forward primer 515 and reverse primer 806 following the Earth Microbiome Project protocol (http://www.earthmicrobiome.org/). These primers (515F and 806R) carry unique barcodes that allow for multiplexed sequencing. Concentration of the PCR products was measured using a Qubit dsDNA HS assay kit (ThermoFisher, Q32854) and a Promega GloMax plate reader. Equimolar 16S rRNA PCR products for up to 384 samples were pooled prior to sequencing. Sequencing was performed by the Duke Sequencing and Genomic Technologies (SGT) Shared Resource on an Illumina NovaSeq instrument configured for 250 base-pair paired-end sequencing runs on a S Prime lane. Fecal DNA extraction, 16S rRNA library preparation, and sequencing, was performed at the Duke Microbiome Core laboratories.

Fecal DNA from a subset of 396 samples was submitted for metagenomic sequencing at the Novogene Corporation, Inc., using the following protocol. Genomic DNA was randomly fragmented by sonication, then DNA fragments were end polished, A-tailed, and ligated with the full-length adapters of Illumina sequencing,

and followed by further PCR amplification with P5 and indexed P7 oligos. The PCR products as the final construction of the libraries were purified with AMPure XP system. Then libraries were checked for size distribution by Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA), and quantified by real-time PCR (to meet the criteria of 3 nM). The qualified libraries were fed into Illumina sequencers after pooling according to its effective concentration and expected data volume. The raw sequenced reads were then filtered to remove reads that contained adapters, reads containing greater than 10% unidentified bases, and reads with a quality score <5, or over 50% of the total bases. This resulted in a total output of 2871.0 Gb of raw data.

Fecal microbiome transplant experiments: Gnotobiotic experiments were conducted at the Duke Gnotobiotic Core Facility or the National Gnotobiotic Rodent Resource Center in the Center for Gastrointestinal Biology and Disease at the University of North Carolina at Chapel Hill. Human fecal samples were prepared for animal gavage as described (75). Briefly, upon receipt, samples were initially frozen at -80°C and then thawed, opened in a flexible film anaerobic chamber (Coy Laboratory Products, Grass Lake, Michigan), homogenized with a sterile plastic loop, and distributed into 2 ml cryovials in ~200 mg aliquots without preservative. Samples were then stored at -80°C. Immediately before fecal transplant, samples were thawed, resuspended into 10% weight per volume sterile PBS +0.05% cysteine, vortexed repeatedly, allowed to settle at room temp for 5-10 min, and supernatant was then removed for gavage. Three, four, or five male germ-free C57Bl/6 mice between 5-7 weeks of age received between 150 and 200 µl of gavage slurry for each human sample administered. Mice were then housed with ALPHA-Dri (Shepherd Specialty Papers) bedding for two weeks in sterile filter top cages and fed autoclaved Teklad 2020SX diet (Envigo) and water ad libitum. Mice were weighed at gavage and every 3-4 days following fecal transplant. At 2 weeks, mice were euthanized by isoflurane overdose and immediately exsanguinated by cardiac puncture. Fecal samples and tissues were removed and immediately snap frozen in liquid nitrogen, with between 5- and 7-min elapsing between euthanasia and complete tissue removal. Serum and tissue targeted metabolites were measured as described above and as previously published (23).

Study Approval: Recruitment of participants and handling of clinical samples was approved as part of the Pediatric Obesity Microbiome and Metabolism Study (POMMS) (Clinical trial identifier # NCT03139877 and described in detail in (23). Written informed consent was received prior to participation and prior to inclusion of serum and fecal samples for further study in the POMMS biobank. Data, serum, and stool samples from the study participants have been banked and are available (repository study Clinical trials identifier NCT02959034) for further research as described at https://sites.duke.edu/pomms/. All deidentified raw data is available upon request. All animal experiments were done either at the Duke University Gnotobiotic Core or in the National Gnotobiotic Rodent Research Center at the Center for Gastrointestinal Biology and Disease at the University of North Carolina Chapel Hill in AAALAC-accredited facilities and according to IACUC-approved protocols.

Statistical Analysis. Clinical lab measures and targeted metabolites were log-transformed to ensure the assumption of normality of the residuals was met. Any metabolite with missing values in 25% of samples was removed from the analysis. Remaining metabolite levels with missing reads had values imputed at half the minimum result (76). The association between case-control status and each clinical lab measure, controlling for age, sex, and race/ethnicity, was assessed using a linear regression model. To evaluate the metabolic status of study participants, serum levels of 65 targeted metabolites were investigated for associations with the clinical measures of health %95th BMI, HOMA-IR score, HbA1c, and CRP at baseline using linear regression models adjusting for age, sex, and race/ethnicity. Next, we assessed whether the association between case-control status and each metabolite varied by age, sex, or race using linear regression model with the interaction between status and age, sex, or race in separate models. If the overall interaction was statistically significant ($p<0.05$), pairwise comparisons were reported. Lastly, the association between change in each clinical outcome (%95th BMI, HOMA-IR score, HbA1C, and CRP) and change in each metabolite between baseline and 6-months were assessed using linear regression models adjusting for age, sex, race/ethnicity, and baseline clinical outcome. All analyses were conducted in R 4.1 (R Core Team, 2022). Microbiome analysis included PERMANOVA (R package vegan)

Data availability. Raw unprocessed and log-transformed data can be found in Supplemental Data attached to this article. Code used to generate data analysis derived from fecal metagenomic sequencing can be found at (**link forthcoming**). All raw sequencing data can be accessed via (**link forthcoming).** Any other data will be shared upon request.

ACKNOWLEDGEMENTS:

The authors are grateful to Kristin Cleveland, Jamison Cameron, Brittany McAdams, and staff in the Duke Gnotobiotic Core in the Division of Laboratory Animal Resources in the Duke University School of Medicine, and Jeremy Herzog, Josh Marc Frost, and R. Balfour Sartor in the National Gnotobiotic Rodent Resource Center in the Center for Gastrointestinal Biology and Disease at the University of North Carolina at Chapel Hill which is supported by P30-DK034987. We also thank staff at the Duke Microbiome Core laboratories for their assistance in preparing samples for high throughput sequencing.

TABLES

Table 1. Clinical lab values comparing OB versus HWC at baseline

	HWC	OB	Total	Ratio of geometric means (95% CI) (OB compared to control)	P-value*
	N=67	N=220	N=287		
Baseline ALT				1.65 (1.43, 1.89)	<0.001
Mean (SD)	14.6 (6.7)	24.7 (31.8)	22.9 (29.1)		
Median (Q1, Q3)	13.0 (11.0, 15.2)	20.0 (15.0, 25.0)	18.0 (14.0, 24.0)		
(Min, Max)	(6.0, 44.0)	(10.0, 456.0)	(6.0, 456.0)		
Missing	19 (28.4%)	4 (1.8%)	23 (8.0%)		
Baseline HbA1c				1.04 (1.01, 1.07)	0.007
Mean (SD)	5.3 (0.3)	5.6 (0.6)	5.5 (0.5)		
Median (Q1, Q3)	5.3 (5.2, 5.5)	5.5 (5.3, 5.7)	5.5 (5.2, 5.7)		
(Min, Max)	(4.4, 6.0)	(4.5, 11.7)	(4.4, 11.7)		
Missing	20 (29.9%)	10 (4.5%)	30 (10.5%)		

Baseline LDL				1.16 (1.05, 1.28)	0.003
Mean (SD)	88.0 (27.3)	97.0 (25.7)	95.3 (26.2)		
Median (Q1, Q3)	82.0 (72.0, 101.0)	94.0 (80.2, 111.0)	92.0 (78.0, 110.0)		
(Min, Max)	(38.0, 168.0)	(9.0, 195.0)	(9.0, 195.0)		
Missing	18 (26.9%)	6 (2.7%)	24 (8.4%)		
Baseline HDL				0.84 (0.78, 0.90)	<0.001
Mean (SD)	53.7 (12.3)	45.9 (10.1)	47.3 (10.9)		
Median (Q1, Q3)	51.0 (45.0, 59.0)	45.0 (39.0, 52.0)	46.0 (40.0, 53.0)		
(Min, Max)	(36.0, 100.0)	(27.0, 77.0)	(27.0, 100.0)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
Baseline triglyceride				1.31 (1.14, 1.52)	<0.001
Mean (SD)	84.3 (43.6)	111.6 (56.7)	106.5 (55.4)		
Median (Q1, Q3)	72.0 (52.0, 97.0)	97.0 (73.0, 139.0)	91.0 (69.0, 133.8)		
(Min, Max)	(29.0, 223.0)	(22.0, 404.0)	(22.0, 404.0)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
Baseline TG/HDL ratio				1.57 (1.32, 1.87)	<0.001
Mean (SD)	1.7 (1.1)	2.6 (1.7)	2.5 (1.6)		
Median (Q1, Q3)	1.3 (0.9, 2.1)	2.1 (1.5, 3.2)	2.0 (1.3, 3.1)		
(Min, Max)	(0.5, 5.9)	(0.4, 11.9)	(0.4, 11.9)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
Baseline C-reactive protein				6.58 (4.34, 9.97)	<0.001
Mean (SD)	0.2 (0.7)	0.6 (0.9)	0.5 (0.9)		
Median (Q1, Q3)	0.0 (0.0, 0.1)	0.3 (0.1, 0.6)	0.2 (0.1, 0.5)		
(Min, Max)	(0.0, 4.4)	(0.0, 6.9)	(0.0, 6.9)		
Missing	20 (29.9%)	7 (3.2%)	27 (9.4%)		
Baseline insulin				1.82 (1.46, 2.25)	<0.001
Mean (SD)	11.3 (10.1)	19.0 (17.3)	17.5 (16.5)		
Median (Q1, Q3)	7.7 (5.6, 12.2)	15.4 (10.6, 21.8)	13.9 (8.6, 20.5)		
(Min, Max)	(3.4, 52.0)	(3.2, 150.0)	(3.2, 150.0)		
Missing	20 (29.9%)	25 (11.4%)	45 (15.7%)		
Baseline glucose				1.03 (0.99, 1.07)	0.117
Mean (SD)	86.7 (9.0)	88.8 (15.3)	88.4 (14.3)		
Median (Q1, Q3)	87.0 (83.0, 93.0)	87.0 (83.0, 92.0)	87.0 (83.0, 92.0)		
(Min, Max)	(64.0, 108.0)	(69.0, 264.0)	(64.0, 264.0)		
Missing	18 (26.9%)	5 (2.3%)	23 (8.0%)		
Systolic Blood Pressure				1.04 (1.02, 1.07)	<0.001
Mean (SD)	110.9 (10.9)	113.0 (9.7)	112.5 (10.0)		
Median (Q1, Q3)	110.0 (102.0, 120.0)	112.0 (108.0, 120.0)	112.0 (106.0, 120.0)		
(Min, Max)	(90.0, 151.0)	(80.0, 140.0)	(80.0, 151.0)		
Missing	0 (0%)	1 (0.5%)	1 (0.3%)		
Diastolic Blood Pressure					
Mean (SD)	65.7 (8.1)	68.9 (7.7)	68.1 (7.9)	1.07 (1.04, 1.11)	<0.001
Median (Q1, Q3)	64.0 (60.0, 70.5)	70.0 (62.0, 73.5)	68.0 (62.0, 72.0)		

(Min, Max)	(48.0, 82.0)	(50.0, 96.0)	(48.0, 96.0)
Missing	0 (0%)	1 (0.5%)	1 (0.3%)

Table 2. Taxa significantly associated with percent adipose tissue in mice at 2 weeks post FMT

Family	Genus	Species	ASV	Effect Size	P adj
Lachnospiraceae	*Hungatella*	*hathewayii*	ASV_51	3.59	0.001
Oscillospiraceae	*Colidextribacter*	NA	ASV_203	-2.90	0.046
Eggerthellaceae	*Gordonibacter*	NA	ASV_200	-2.71	0.021
Lachnospiraceae	*NA*	NA	ASV_119	15.78	0.024
Akkermansiaceae	*Akkermansia*	NA	ASV_4	3.06	0.046

FIGURE LEGENDS

Figure 1. Significant metabolic changes are associated with clinical measures of obesity in adolescents. **A**. POMMS study overview depicting the inclusion criteria, sampling schedule for both the healthy weight control (HWC) and participants with obesity (OB). **B-D**. Linear regression analysis adjusted for age, race and sex of participant. See Statistical Analysis description in Methods for details. **B**. Targeted serum metabolites associated with %95th BMI, **C.** Hemoglobin A1c (HbA1c), **D**. Homeostatic Insulin Resistance score (HOMA-IR), at baseline, or **E.** C-Reactive Protein (CRP), at baseline. For **B-E**, metabolites above the dotted line are considered significantly associated with the noted clinical measure. Higher levels of metabolites in the right upper quadrant are significantly associated with higher levels of the clinical measure. In comparison, higher levels of metabolites in the left upper quadrant are significantly associated with lower levels of the clinical measure. %95th BMI is defined as the percent of the BMI above the 95th percentile.

Figure 2. Branched Chain Amino Acids (BCAA) and related metabolite levels are sex dependent, significantly different in HWC v OB cohorts, and unique to adolescents with obesity. A. BCAA related metabolism pathway. Valine (VAL), Leucine (LEU) and Isoleucine (ILE) are reversibly transaminated by the branched chain amino acid transferase (BCAT2) in the mitochondria to their respective ketoacids ketoisovalerate (KIV), ketoisocaproate (KIC) and ketomethylvalerate (KMV). The amino group removed from the BCAA is transferred to α-ketoglutarate (α-KG), yielding glutamate (GLU). The ketoacids can then be irreversibly hydrolyzed by the branched chain ketoacid dehydrogenase (BCKDH) where BCAA derived carbons can then enter the TCA cycle or contribute to lipogenesis. When BCAA are elevated, as in obesity, excess BCAA increases BCAT2 activity which could result in an increased nitrogen load, especially in muscle tissues. This load can be relieved, most likely via coordinated action of serine dehydratase, serine hydroxymethyltransferase, and glycine acyltransferase. Resulting increased metabolites, such as glutamine (GLN) and acylglycine can be secreted from the affected tissues. ALA, alanine; PYR, pyruvate. **B-J**. Levels of serum amino acids and keto acids associated with BCAA and alanine-pyruvate metabolism in HWC v OB cohorts divided by sex. Statistics were performed on mean metabolite values following log transformation, and P values result from Mann-Whitney tests and are corrected for multiple comparisons. **, P<0.01; ***, P<0.001; ****, P<0.0001.

Figure 3. Sex-dependent differences in serum ketoacids are less evident in younger children than in more mature adolescents. Log-transformed levels of serum metabolites tested for significance in an overall interaction and between **A**. sex and HWC v OB status; **B**. Tanner (puberty) stage and HWC v OB status; and **C.** Young age (9 y or younger) versus older age metabolites and sex. Only significant metabolites are shown, P ≤ 0.05, after adjustment for race and multiple comparisons. Complete metabolite results are shown in Supplemental Tables S2, S2.1, S3, and S3.1). See Statistical Analysis methods for details.

Figure 4. **Several gut microbial taxa and predicted enzymatic functions are associated with clinical variables at baseline. A**. Abundance of microbial species determined by fecal metagenomic sequencing that were positively or negatively significantly associated with %95th BMI at baseline. **B**. Venn diagram showing shared and distinct numbers of fecal microbial species associated with %95th BMI, insulin resistance score (HOMA-IR) and C-reactive protein (CRP) levels at baseline. **C**. Linear regression correlation following dimensionality reduction between co-varying microbial factors and clinical variables at baseline. Factors are named for prominent taxa within each cluster, and the underlying taxa and weights in each cluster is listed in Supplemental Tables 4.1-4.4.

Figure 5. **Fecal microbial transplants from adolescent POMMS study participants did not significantly affect weight gain in recipient mice but did influence serum metabolites**. **A**. Experimental design. Groups of 3-5 six-week-old male germ-free mice were weighed and gavaged with a slurry of baseline fecal material from one of 5 HWC or 9 OB POMMS participants. Mice were weighed every 3-4 days and sacrificed at 14 days post gavage. **B.** Average weight and standard deviation of each group of mice over the 2 weeks post gavage period. **C**. Mouse serum metabolites associated with percent weight gain over the FMT incubation period. Labeled dots above the dashed line represent metabolites significantly associated with less weight gain over time following linear regression analysis. **D.** Mean percent weight gain of all mice grouped by donor (HWC v OB) at baseline. **E.** Mean epidydimal fat pad weight grouped by donor at baseline. **F.** Mean percent epidydimal fat pad weight grouped by donor at baseline. **G.** Fecal microbial taxa were identified by 16S rRNA gene sequencing. ASV significantly associated ($P \leq 0.05$ after adjustment for multiple comparisons) with clustered mouse serum metabolites (Fig S6) using ANCOM-BC (34) are shown on the heatmap. Clusters are described by the predominant metabolite species in each cluster. Each taxon in the heatmap represents a unique ASV identified to the lowest classification possible. BCAA, branched chain amino acids; AC, acylcarnitines.

Figure 6. Serum aromatic amino acids increase with BMI and HOMA-IR scores over the 6 month observational study period, while several even chain acylcarnitines and glycine go up with clinical improvements. **A**. Absolute change in %95th BMI in OB cohort participants over the observational study period. **B**. Percent change in HOMA-IR over the observational study period. **C**. Graph of change in %95th BMI and percent change in HOMA-IR over the observational study period. **D-F**. Estimated coefficients for metabolite levels associated with change in %95th BMI (**D**), Percent change in HOMA-IR (**E**), or change in CRP (**F**) after adjusting for age, race, sex, and baseline measurement. For **D-F**, acylcarnitines are labeled in black, amino acids are labeled in purple, and ketoacids are labeled in green.

Figure 7. Microbial taxa associated with longitudinal outcomes. **A**. Differential abundance of microbial taxa at baseline associated with change in %95th BMI over the 6 month observational period. **B**. Venn diagram of microbial taxa shared between changes in clinical outcomes over the study period. See Statistical Analysis methods for details.

LITERATURE CITED

1. Felig P, Marliss E, Cahill GF, Jr. 1969. Plasma amino acid levels and insulin secretion in obesity. *N Engl J Med* 281: 811-6
2. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. 2011. Metabolite profiles and the risk of developing diabetes. *Nat Med* 17: 448-53
3. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS, Jr., Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. 2009. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab* 9: 311-26
4. Menni C, Fauman E, Erte I, Perry JR, Kastenmuller G, Shin SY, Petersen AK, Hyde C, Psatha M, Ward KJ, Yuan W, Milburn M, Palmer CN, Frayling TM, Trimmer J, Bell JT, Gieger C, Mohney RP, Brosnan MJ, Suhre K, Soranzo N, Spector TD. 2013. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. *Diabetes* 62: 4270-6
5. Batch BC, Shah SH, Newgard CB, Turer CB, Haynes C, Bain JR, Muehlbauer M, Patel MJ, Stevens RD, Appel LJ, Newby LK, Svetkey LP. 2013. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. *Metabolism* 62: 961-9

6. Glynn EL, Piner LW, Huffman KM, Slentz CA, Elliot-Penry L, AbouAssi H, White PJ, Bain JR, Muehlbauer MJ, Ilkayeva OR, Stevens RD, Porter Starr KN, Bales CW, Volpi E, Brosnan MJ, Trimmer JK, Rolph TP, Newgard CB, Kraus WE. 2015. Impact of combined resistance and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in overweight humans. *Diabetologia* 58: 2324-35
7. Hernandez-Alvarez MI, Diaz-Ramos A, Berdasco M, Cobb J, Planet E, Cooper D, Pazderska A, Wanic K, O'Hanlon D, Gomez A, de la Ballina LR, Esteller M, Palacin M, O'Gorman DJ, Nolan JJ, Zorzano A. 2017. Early-onset and classical forms of type 2 diabetes show impaired expression of genes involved in muscle branched-chain amino acids metabolism. *Sci Rep* 7: 13850
8. Kobayashi R, Shimomura Y, Murakami T, Nakai N, Fujitsuka N, Otsuka M, Arakawa N, Popov KM, Harris RA. 1997. Gender difference in regulation of branched-chain amino acid catabolism. *Biochem J* 327 (Pt 2): 449-53
9. Neinast M, Murashige D, Arany Z. 2019. Branched Chain Amino Acids. *Annu Rev Physiol* 81: 139-64
10. White PJ, Lapworth AL, An J, Wang L, McGarrah RW, Stevens RD, Ilkayeva O, George T, Muehlbauer MJ, Bain JR, Trimmer JK, Brosnan MJ, Rolph TP, Newgard CB. 2016. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. *Mol Metab* 5: 538-51
11. Morris C, O'Grada C, Ryan M, Roche HM, Gibney MJ, Gibney ER, Brennan L. 2012. The relationship between BMI and metabolomic profiles: a focus on amino acids. *Proc Nutr Soc* 71: 634-8
12. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG, DeLany JP. 2010. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. *Obesity (Silver Spring)* 18: 1695-700
13. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, Sun C, Cheung M, Viikari JS, Dwyer T, Raitakari OT. 2011. Childhood adiposity, adult adiposity, and cardiovascular risk factors. *N Engl J Med* 365: 1876-85
14. Tirosh A, Shai I, Afek A, Dubnov-Raz G, Ayalon N, Gordon B, Derazne E, Tzur D, Shamis A, Vinker S, Rudich A. 2011. Adolescent BMI trajectory and risk of diabetes versus coronary disease. *N Engl J Med* 364: 1315-25
15. Butte NF, Liu Y, Zakeri IF, Mohney RP, Mehta N, Voruganti VS, Goring H, Cole SA, Comuzzie AG. 2015. Global metabolomic profiling targeting childhood obesity in the Hispanic population. *Am J Clin Nutr* 102: 256-67
16. Gumus Balikcioglu P, Jachthuber Trub C, Balikcioglu M, Ilkayeva O, White PJ, Muehlbauer M, Bain JR, Armstrong S, Freemark M. 2022. Branched-chain alpha-keto acids and glutamate/glutamine: Biomarkers of insulin resistance in childhood obesity. *Endocrinol Diabetes Metab*
17. Hernandez N, Lokhnygina Y, Ramaker ME, Ilkayeva O, Muehlbauer MJ, Crawford ML, Grant RP, Hsia DS, Jain N, Bain JR, Armstrong S, Newgard CB, Freemark M, Gumus Balikcioglu P. 2024. Sex Differences in Branched-chain Amino Acid and Tryptophan Metabolism and Pathogenesis of Youth-onset Type 2 Diabetes. *J Clin Endocrinol Metab* 109: e1345-e58
18. Cani PD, Van Hul M. 2024. Gut microbiota in overweight and obesity: crosstalk with adipose tissue. *Nat Rev Gastroenterol Hepatol* 21: 164-83
19. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 444: 1027-31
20. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. 2008. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell Host Microbe* 3: 213-23
21. Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T, Fandriks L, le Roux CW, Nielsen J, Backhed F. 2015. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. *Cell Metab* 22: 228-38
22. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI.

2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science* 341: 1241214
23. McCann JR, Bihlmeyer NA, Roche K, Catherine C, Jawahar J, Kwee LC, Younge NE, Silverman J, Ilkayeva O, Sarria C, Zizzi A, Wootton J, Poppe L, Anderson P, Arlotto M, Wei Z, Granek JA, Valdivia RH, David LA, Dressman HK, Newgard CB, Shah SH, Seed PC, Rawls JF, Armstrong SC. 2021. The Pediatric Obesity Microbiome and Metabolism Study (POMMS): Methods, Baseline Data, and Early Insights. *Obesity (Silver Spring)* 29: 569-78
24. Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, Avila Edwards KC, Eneli I, Hamre R, Joseph MM, Lunsford D, Mendonca E, Michalsky MP, Mirza N, Ochoa ER, Sharifi M, Staiano AE, Weedn AE, Flinn SK, Lindros J, Okechukwu K. 2023. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics* 151
25. Jachthuber Trub C, Balikcioglu M, Freemark M, Bain J, Muehlbauer M, Ilkayeva O, White PJ, Armstrong S, Ostbye T, Grambow S, Gumus Balikcioglu P. 2021. Impact of lifestyle Intervention on branched-chain amino acid catabolism and insulin sensitivity in adolescents with obesity. *Endocrinol Diabetes Metab* 4: e00250
26. Lelis DF, Calzavara JVS, Santos RD, Sposito AC, Griep RH, Barreto SM, Molina M, Schmidt MI, Duncan BB, Bensenor I, Lotufo PA, Mill JG, Baldo MP. 2021. Reference values for the triglyceride to high-density lipoprotein ratio and its association with cardiometabolic diseases in a mixed adult population: The ELSA-Brasil study. *J Clin Lipidol* 15: 699-711
27. Nur Zati Iwani AK, Jalaludin MY, Yahya A, Mansor F, Md Zain F, Hong JYH, Wan Mohd Zin RM, Mokhtar AH. 2022. TG: HDL-C Ratio as Insulin Resistance Marker for Metabolic Syndrome in Children With Obesity. *Front Endocrinol (Lausanne)* 13: 852290
28. Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, Houssier M, Roussel B, Besse-Patin A, Combes M, Mir L, Monbrun L, Bezaire V, Prunet-Marcassus B, Waget A, Vila I, Caspar-Bauguil S, Louche K, Marques MA, Mairal A, Renoud ML, Galitzky J, Holm C, Mouisel E, Thalamas C, Viguerie N, Sulpice T, Burcelin R, Arner P, Langin D. 2013. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. *PLoS Biol* 11: e1001485
29. Jehan S, Zizi F, Pandi-Perumal SR, McFarlane SI, Jean-Louis G, Myers AK. 2020. Energy imbalance: obesity, associated comorbidities, prevention, management and public health implications. *Adv Obes Weight Manag Control* 10: 146-61
30. Kelsey MM, Zeitler PS, Drews K, Chan CL. 2020. Normal Hemoglobin A1c Variability in Early Adolescence: Adult Criteria for Prediabetes Should Be Applied with Caution. *J Pediatr* 216: 232-5
31. Emmanuel M, Bokor BR. 2023. Tanner Stages. In *StatPearls*. Treasure Island (FL)
32. Armstrong SC, Windom M, Bihlmeyer NA, Li JS, Shah SH, Story M, Zucker N, Kraus WE, Pagidipati N, Peterson E, Wong C, Wiedemeier M, Sibley L, Berchuck SI, Merrill P, Zizzi A, Sarria C, Dressman HK, Rawls JF, Skinner AC. 2020. Rationale and design of "Hearts & Parks": study protocol for a pragmatic randomized clinical trial of an integrated clinic-community intervention to treat pediatric obesity. *BMC Pediatr* 20: 308
33. Fernandes AD, Reid JN, Macklaim JM, McMurrough TA, Edgell DR, Gloor GB. 2014. Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis. *Microbiome* 2: 15
34. Lin H, Eggesbo M, Peddada SD. 2022. Linear and nonlinear correlation estimators unveil undescribed taxa interactions in microbiome data. *Nat Commun* 13: 4946
35. Martin BD, Witten D, Willis AD. 2020. Modeling Microbial Abundances and Dysbiosis with Beta-Binomial Regression. *Ann Appl Stat* 14: 94-115
36. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, Forslund K, Hildebrand F, Prifti E, Falony G, Le Chatelier E, Levenez F, Dore J, Mattila I, Plichta DR, Poho P, Hellgren LI, Arumugam M, Sunagawa S, Vieira-Silva S, Jorgensen T, Holm JB, Trost K, Meta HITC, Kristiansen K, Brix S, Raes J, Wang J, Hansen T, Bork P, Brunak S, Oresic M, Ehrlich SD, Pedersen O. 2016. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature* 535: 376-81

37. Zhang Z, Mocanu V, Cai C, Dang J, Slater L, Deehan EC, Walter J, Madsen KL. 2019. Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome-A Systematic Review. *Nutrients* 11
38. Mardinoglu A, Gogg S, Lotta LA, Stancakova A, Nerstedt A, Boren J, Bluher M, Ferrannini E, Langenberg C, Wareham NJ, Laakso M, Smith U. 2018. Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes. *EBioMedicine* 27: 151-5
39. Cook JS, Hoffman RP, Stene MA, Hansen JR. 1993. Effects of maturational stage on insulin sensitivity during puberty. *J Clin Endocrinol Metab* 77: 725-30
40. Moran A, Jacobs DR, Jr., Steinberger J, Hong CP, Prineas R, Luepker R, Sinaiko AR. 1999. Insulin resistance during puberty: results from clamp studies in 357 children. *Diabetes* 48: 2039-44
41. Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH. 1995. Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. *J Clin Endocrinol Metab* 80: 172-8
42. Harrison C, Peyyety V, Rodriguez Gonzalez A, Chivate R, Qin X, Zupa MF, Ragavan MI, Vajravelu ME. 2024. Prediabetes Prevalence by Adverse Social Determinants of Health in Adolescents. *JAMA Netw Open* 7: e2416088
43. Palmer ND, Stevens RD, Antinozzi PA, Anderson A, Bergman RN, Wagenknecht LE, Newgard CB, Bowden DW. 2015. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. *J Clin Endocrinol Metab* 100: E463-8
44. Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, Muehlbauer MJ, Wenner BR, Bain JR, Laferrere B, Gorroochurn P, Teixeira J, Brantley PJ, Stevens VJ, Hollis JF, Appel LJ, Lien LF, Batch B, Newgard CB, Svetkey LP. 2012. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. *Diabetologia* 55: 321-30
45. Magkos F, Bradley D, Schweitzer GG, Finck BN, Eagon JC, Ilkayeva O, Newgard CB, Klein S. 2013. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. *Diabetes* 62: 2757-61
46. Laferrere B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, Bose M, Teixeira J, Stevens RD, Wenner BR, Bain JR, Muehlbauer MJ, Haqq A, Lien L, Shah SH, Svetkey LP, Newgard CB. 2011. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. *Sci Transl Med* 3: 80re2
47. She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ. 2007. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. *Am J Physiol Endocrinol Metab* 293: E1552-63
48. White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, Grenier-Larouche T, An J, Lapworth AL, Astapova I, Hannou SA, George T, Arlotto M, Olson LB, Lai M, Zhang GF, Ilkayeva O, Herman MA, Wynn RM, Chuang DT, Newgard CB. 2018. The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase. *Cell Metab* 27: 1281-93 e7
49. Bacha F, El-Ayash H, Mohamad M, Sharma S, Puyau M, Kanchi R, Coarfa C. 2024. Distinct Amino Acid Profile Characterizes Youth With or at Risk for Type 2 Diabetes. *Diabetes* 73: 628-36
50. Krumsiek J, Mittelstrass K, Do KT, Stuckler F, Ried J, Adamski J, Peters A, Illig T, Kronenberg F, Friedrich N, Nauck M, Pietzner M, Mook-Kanamori DO, Suhre K, Gieger C, Grallert H, Theis FJ, Kastenmuller G. 2015. Gender-specific pathway differences in the human serum metabolome. *Metabolomics* 11: 1815-33
51. Lamont LS, McCullough AJ, Kalhan SC. 2001. Gender differences in leucine, but not lysine, kinetics. *J Appl Physiol (1985)* 91: 357-62
52. Newbern D, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, Ilkayeva O, Dolinsky D, Armstrong S, Irizarry K, Freemark M. 2014. Sex differences in biomarkers associated with insulin resistance in obese adolescents: metabolomic profiling and principal components analysis. *J Clin Endocrinol Metab* 99: 4730-9
53. Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A. 2018. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. *Hepatology* 67: 145-58

54. Labonte CC, Farsijani S, Marliss EB, Gougeon R, Morais JA, Pereira S, Bassil M, Winter A, Murphy J, Combs TP, Chevalier S. 2017. Plasma Amino Acids vs Conventional Predictors of Insulin Resistance Measured by the Hyperinsulinemic Clamp. *J Endocr Soc* 1: 861-73
55. Takashina C, Tsujino I, Watanabe T, Sakaue S, Ikeda D, Yamada A, Sato T, Ohira H, Otsuka Y, Oyama-Manabe N, Ito YM, Nishimura M. 2016. Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance. *Nutr Metab (Lond)* 13: 5
56. Gralka E, Luchinat C, Tenori L, Ernst B, Thurnheer M, Schultes B. 2015. Metabolomic fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-dependent manner. *Am J Clin Nutr* 102: 1313-22
57. Tulipani S, Griffin J, Palau-Rodriguez M, Mora-Cubillos X, Bernal-Lopez RM, Tinahones FJ, Corkey BE, Andres-Lacueva C. 2016. Metabolomics-guided insights on bariatric surgery versus behavioral interventions for weight loss. *Obesity (Silver Spring)* 24: 2451-66
58. White PJ, Lapworth AL, McGarrah RW, Kwee LC, Crown SB, Ilkayeva O, An J, Carson MW, Christopher BA, Ball JR, Davies MN, Kjalarsdottir L, George T, Muehlbauer MJ, Bain JR, Stevens RD, Koves TR, Muoio DM, Brozinick JT, Gimeno RE, Brosnan MJ, Rolph TP, Kraus WE, Shah SH, Newgard CB. 2020. Muscle-Liver Trafficking of BCAA-Derived Nitrogen Underlies Obesity-Related Glycine Depletion. *Cell Rep* 33: 108375
59. Zhang S, Zeng X, Ren M, Mao X, Qiao S. 2017. Novel metabolic and physiological functions of branched chain amino acids: a review. *J Anim Sci Biotechnol* 8: 10
60. Hosseinkhani S, Salari P, Bandarian F, Asadi M, Shirani S, Najjar N, Dehghanbanadaki H, Pasalar P, Razi F. 2022. Circulating amino acids and acylcarnitines correlated with different CAC score ranges in diabetic postmenopausal women using LC-MS/MS based metabolomics approach. *BMC Endocr Disord* 22: 186
61. Kanmani S, Kwon M, Shin MK, Kim MK. 2019. Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study. *Sci Rep* 9: 4573
62. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, Luben R, Bingham S, Khaw KT, Wareham NJ. 2009. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. *Diabetologia* 52: 1040-7
63. Tam CS, Clement K, Baur LA, Tordjman J. 2010. Obesity and low-grade inflammation: a paediatric perspective. *Obes Rev* 11: 118-26
64. Nappo A, Iacoviello L, Fraterman A, Gonzalez-Gil EM, Hadjigeorgiou C, Marild S, Molnar D, Moreno LA, Peplies J, Sioen I, Veidebaum T, Siani A, Russo P. 2013. High-sensitivity C-reactive protein is a predictive factor of adiposity in children: results of the identification and prevention of dietary- and lifestyle-induced health effects in children and infants (IDEFICS) study. *J Am Heart Assoc* 2: e000101
65. Selvin E, Paynter NP, Erlinger TP. 2007. The effect of weight loss on C-reactive protein: a systematic review. *Arch Intern Med* 167: 31-9
66. McCann JR, Rawls JF. 2023. Essential Amino Acid Metabolites as Chemical Mediators of Host-Microbe Interaction in the Gut. *Annu Rev Microbiol* 77: 479-97
67. Alves A, Bassot A, Bulteau AL, Pirola L, Morio B. 2019. Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases. *Nutrients* 11
68. Dai ZL, Wu G, Zhu WY. 2011. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. *Front Biosci (Landmark Ed)* 16: 1768-86
69. Agans R, Rigsbee L, Kenche H, Michail S, Khamis HJ, Paliy O. 2011. Distal gut microbiota of adolescent children is different from that of adults. *FEMS Microbiol Ecol* 77: 404-12
70. Cox AJ, West NP, Cripps AW. 2015. Obesity, inflammation, and the gut microbiota. *Lancet Diabetes Endocrinol* 3: 207-15
71. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. 2005. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* 102: 11070-5
72. Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G, Putignani L. 2018. Gut

Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns. *Front Microbiol* 9: 1210
73. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28: 412-9
74. Olson KC, Chen G, Lynch CJ. 2013. Quantification of branched-chain keto acids in tissue by ultra fast liquid chromatography-mass spectrometry. *Anal Biochem* 439: 116-22
75. Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A, Dantas G, Gordon JI. 2011. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. *Proc Natl Acad Sci U S A* 108: 6252-7
76. Wei R, Wang J, Su M, Jia E, Chen S, Chen T, Ni Y. 2018. Missing Value Imputation Approach for Mass Spectrometry-based Metabolomics Data. *Sci Rep* 8: 663

Figure 1


A
The Pediatric Obesity Microbiome and Metabolism Study (POMMS)
Healthy Weight Control (HWC)
BMI: 5-85th%ile, ages 10-18
Entered puberty (Tanner 2)
Recruited from primary care
Adolescents with Obesity (OB)
BMI: ≥95%ile, ages 10-18
Entered puberty (Tanner 2)
24-week Observational "Healthy Lifestyles" Trial #NCT03139877
Sampling Schedule:
Baseline Sample only
Baseline
6 weeks
12 weeks
18 weeks
24 weeks
B
%95th BMI
-log Adj P-value
Mean EST
Gly
Ser
KMV
KIC
C18
Tyr
Val
Glx
Phe
C20
C3
C8:1
C6-DC/C8-OH
His
Met
C10-OH/C8-DC
C14:1-OH
Arg
C5
C14-OH/C12-DC
Leu/Ile
KIV
C
HbA1c
Amino Acid
Ketoacid
Acylcarnitine
C14
C16:2
C16:1
C14:1
C18:1
C18:2
C2
C18:2-OH
C6-DC/C8-OH
C8:1-OH/C6:1-DC
Leu/Ile
Phe
Tyr
Ala
Val
Arg
Gly
C5
Ser
C3
KIV
KIC
KMV
D
HOMA-IR
C6-DC/C8-OH
C12-OH/C10-DC
Glx
Tyr
Phe
C12
C14:2
C10-OH/C8-DC
Ala
Ser
C18:1
C16:2
C20
Pro
Leu/Ile
Gly
Val
C3
C4/C4
His
C5
KIV
KMV
KIC
E
CRP
His
Gly
Asx
C20
Ala
Phe
Val
C8:1
KMV
KIC
C3
Leu/Ile
KIV
C5

Figure 2


A
Val
Leu
Ile
BCAT2
α-KG
Ala
Glu
Pyr
NH4
Gln
KIV
KIC
KMV
CoA
CO2
Isobutyryl-CoA
Isovaleryl-CoA
2-Methylbutyryl-CoA
C5-Acylcarnitine
BCKDH
Lipogenesis
Propionyl-CoA
Acetyl-CoA
C3-Acylcarnitine
Succinyl-CoA
Krebs Cycle
B
Val
Log transformed metabolites
C
KIV
D
Leu/Ile
E
KMV
F
KIC
G
Glx
p=0.07
Log transformed values
H
Gly
I
C3
J
C5
M
F
HWC-M
HWC-F
OB-M
OB-F

Figure 3


A
Interaction:
Sex x HWC/OB
Leu/Ile
His
Orn
C18
C20-OH/C18-DC
C16
Cit
C8:1-OH/C6:1-DC
C18:1
Val
Met
Phe
Overal interaction: Sex x HWC/OB
HWC M v F
OB M v F
M OB v HWC
F OB v HWC
Second Stage Tests
P value
0.01 0.03
Mean EST
-0.2 0 0.2
B
Interaction:
Tanner Stage x HWC/OB
C5-DC
KMV
C18:1
C10:3
TS4 OB v HWC
TS5 OB v HWC
Second Stage Tests
P value
0.02 0.04
Mean EST
-0.2 -0.1 0
C
Interaction:
Young Age x Sex
C5-OH/C3-DC
C16:1-OH/C14:1-DC
C3
<9yo M v F
>9yo M v F
M >9yo v <9yo
F >9yo v <9yo
Second Stage Tests
P value
0.01 0.04
Mean EST
-0.3 0 0.3

Figure 4


A
%P95BMI differential abundance
Ruminoccocus lactaris
Akkermansia sp. CAG:344
Alistipes finegoldii
Clostridium sp. AT4
Clostridium sp. CAG:7
Clostridium sp. Marseille-P3244
Drancourtella massiliensis
Faecalibacterium virus Oengus
Lachnospiraceae 3_1_57FAA_CT1
Ligolactobacillus ruminis
Roseburia intestinalis
Ruminococcaceae bacterium cv2
-0.04
-0.02
0.00
0.02
0.04
0.06
B
Shared taxa significantly associated with clinical scores
HOMA-IR
62
Alistipes finegoldii
5
1
1
4
%P95BMI
2
39
CRP
C
F|bacteroidesGroup
R = −0.22, p = 0.00062
F|bacteroidesGroup
R = −0.18, p = 0.006
F|faecalibacteriumGroup
R = 0.21, p = 0.00091
F|faecalibacteriumGroup
R = 0.13, p = 0.055
Score
%P95BMI
CRP

Figure 5


A
Gavage
n=3-5
Experimental Timeline
Time (Days post gavage)
0
3
7
10
14
Gavage
Weigh
Weigh
Weigh
Weigh
Weigh
Tissue harvest
B
FMT sample:
HWC
OB
Grams
Days post colonization
C
Less weight gain
More weight gain
-log adjusted P-value
Spearman R
C10:3
Asx
Tyr
C16:1
Arg
C8:1
C4-DC/Ci4-DC
Gly
C7-DC
C22
D
p=0.1469
mean % weight gain
HWC
OB
E
ns
mean weight adipose (g)
HWC
OB
F
ns
mean % adipose
HWC
OB
G
Akkermansia
Tuzzerella
Flavonifractor plautii
Turicibacter
Lactonifactor
Enterococcus
Blautia glucerasea
Clostridium sensu stricto 1
Romboutsia ilealis
Ruminococcus torques group
Faecalibacterium
Lachnospiraceae
Bacteroides uniformis
Alistipes putredinis
Gordonibacter
Atopobiaceae
Eggerthella lenta
Monoglobus
Lachnoclostridium
Faecalibacterium prausnitzii
Blautia hydrogenotrophica
Anaerostipes caccae
Eisenbergiella tayi
Lachnospiraceae NK4A136 group
Bacteroides
Candidatus
Hungatella hathewayii
Oscillospiraceae
Bilophila wadsworthia
Barnesiella
Bacteroides uniformis
Bacteroides
Bacteroides caccae
Alistipes finegoldii
Bacteroides
Bacteroides
Parabacteroides merdae
Bacteroides
Bacteroides vulgatus
Parasutterella excrementihominis
Escherichia-Shigella
Lachnospiraceae
Lachnospiraceae
Blautia
Lachnospiraceae
GCA-900066575
Blautia
Bacteroides
Lachnospiraceae
+10
0
-10
Amino Acids
Ketoacids
BCAA+Metabolites
Even Chain AC
Decarboxylated AC
Serum Metabolite Cluster

Figure 6


A
Change in %P95 BMI
Participant ID
B
% Change in HOMA-IR
Participant ID
C
% Change in HOMA-IR
Change in %95thBMI
D
Change in %95thBMI
-log adjusted P-value
Mean EST
Amino Acids
Ketoacids
Acylcarnitines
Tyr
C14:1
C16:1
C12
C8:1-DC
C10
C18:1-DC
C8
C14:2
C14:1-OH
C16:2
C10:1
C12-OH/C10-DC
C18:1
C10-OH/C8-DC
Gly
Pro
Val
Leu/Ile
C3
C5
E
Change in HbA1c
Mean EST
C16:1-OH/C14:1-DC
C18:2-OH
Orn
Ser
His
KMV
KIC
KIV
C5
C3
Val
Leu/Ile
Tyr
Phe
F
Change in HOMA-IR
-log adjusted P-value
Mean EST
Tyr
C20:4
Pro
C16
C10
C5-DC
C18:1
C10-OH/C8-DC
C10:3
C5:1
C12
C8:1
Met
Phe
Leu/Ile
C5
C3
Ala
Val
KIC
KMV
KIV
Gly
G
Change in CRP
Mean EST
Gly
Phe
Pro
Met
C12:1
C16:1
C10-OH/C8-DC
C6-DC/C8-OH
His
Cit
Val
Ketoacids
C3
Leu/Ile
C5

Figure 7


A
Baseline taxa signficantly associated with change in %P95BMI
Taxa
[Eubacterium] rectale
[Ruminococcus] torques
Bacteroides cellulosilyticus
Bacteroides finegoldii
Bacteroides thetaiotaomicron
Bacteroides uniformis
Barnesiella intestinihominis
Blautia sp. CAG:52
Clostridium sp. CAG:127
Collinsella sp. 60_9
Coprobacillus sp. 8_2_54BFAA
Coprococcus comes
Dorea longicatena
Enterocloster citroniae
Eubacterium sp. CAG:192
Faecalibacterium sp. CAG:74_58_120
Faecalitalea cylindroides
Firmicutes bacterium CAG:114
Firmicutes bacterium CAG:341
Intestinibacter bartlettii
Olsenella umbonata
Oscillibacter sp. CAG:241
Oscillibacter sp. CAG:241_62_21
Oscillibacter sp. PC13
Parabacteroides distasonis
Parabacteroides merdae
Phascolarctobacterium succinatutens
Prevotella lascolaii
Ruminococcus sp. CAG:330
Ruminococcus sp. CAG:579
Schaalia odontolytica
Subdoligranulum variabile
uncultured Butyricicoccus sp.
uncultured Eubacterium sp.
0.00
0.05
0.10
0.15
0.20


B
Shared taxa associated with change in clinical score
Coprobacillus sp. 8_2__54BFAA
Parabacteroides distasonis
Parabacteroides merdae
B. thetaiotaomicron
B. finegoldii
B. uniformis
Anaerostipes hadrus
Blautia producta
Escherichia virus Lambda_4A7
Firmicutes bacterium CAG:646
ΔCRP
93
6
4
0
28
Δ%P95BMI
0
6
ΔHbA1c
count
75
50
25
0